Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 49: 2012-2019, 2003. First published November 13, 2003; 10.1373/clinchem.2003.020875
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
clinchem.2003.020875v1
49/12/2012    most recent
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via ISI Web of Science (3)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Xiang, S.
Right arrow Articles by Krum, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Xiang, S.
Right arrow Articles by Krum, H.
Related Collections
Right arrow Proteomics and Protein Markers
(Clinical Chemistry. 2003;49:2012-2019.)
© 2003 American Association for Clinical Chemistry, Inc.

Proteomics and Protein Markers

Physiologic Determinants of Endothelin Concentrations in Human Saliva

Sue Xiang1,1, Rachel Denver1, Michael Bailey1 and Henry Krum1,a

1 National Health and Medical Research Council of Australia Center of Clinical Research Excellence in Therapeutics, Department of Medicine and Department of Epidemiology & Preventive Medicine, Monash University, Alfred Hospital, Melbourne, Victoria 3004, Australia.

aAuthor for correspondence. Fax 61-399030556; e-mail henry.krum{at}med.monash.edu.au.

Background: Salivary endothelin (ET) concentrations have been shown to correlate with disease severity in patients with chronic heart failure (CHF). We undertook the present study to evaluate the stability of salivary ET under different handling conditions to assess its suitability as a biochemical marker in screening, diagnosis, and management of CHF.

Methods: Saliva samples were collected from healthy individuals and/or CHF patients, subjected to different handling conditions, and then stored at -80 °C until assayed by an ELISA for ET.

Results: Salivary ET concentrations showed a time-dependent increase during storage at room temperature. After 72 h of incubation at room temperature, ET increased ~2.8-fold (P = 0.03). Simultaneously, salivary big ET showed a time-dependent 11.2-fold decrease (P <0.0001). This activity was blocked by an ET-converting enzyme (ECE) inhibitor, suggesting that these changes were attributable to ECE-dependent cleavage of endogenous big ET in saliva. Ex vivo conversion was also observed when samples were stored at 4 °C, but the magnitude of these changes was markedly smaller (P <0.0001). Posture also affected salivary ET concentrations in CHF patients. With a change from supine to seated rest, salivary ET concentrations increased 1.5- and 1.8-fold after 20 and 40 min, respectively (P = 0.01). With a return to supine rest, salivary ET concentrations returned to baseline concentrations (P = 0.008).

Conclusions: These data suggest that saliva sampling and handling conditions could markedly affect measurement of salivary ET. In particular, care should be taken to minimize ECE-dependent enzymatic conversion of endogenous big ET in saliva.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by the American Association for Clinical Chemistry.